Subt. Form PTO-1449

Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

OF

Docket Number HYB-005US4

Application Number 10/694,383

Group Art Unit

Applicant

1

Kandimalla et al. Filina Date

10/27/03

NA

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/MH/_	5,149,798	09/22/92	Agrawal et al.	536	27	

2

Foreign Patent Documents							
EXAMINER DOCUMENT DATE COUNTRY CLASS SUBC		SUBCLASS	TRANSLATION				
INITIAL	NUMBER		300,000		1 20200002	YES	NO
	WO99/62923		PCT				
/MH/							

			Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)
		C1.	Khorana et al. (1972) "Studies on Polynucleotides," J. Molec. Biol. 72-209
/(МΗ	CS.	Reese (1978) "The Chemical Synthesis of Oligo- and Poly-Nucleotides By The Phosporotriester Approach," Tetrahedron 34:3143-3179
		ප _.	Beaucage et al. (1981) "Deoxynucleoside Phosphoramidites A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," Tetrahedron Lett. 22:1859-1862
		C4 .	Connolly et al. (1984) "Synthesis and Characterization of an Octanucleotide Containing the EcoRi Recognition Sequence With A Phosphorothicate Group At The Cleavage Site," Biochemistry 23:3443
		C5.	Agrawal et al. (1987) "Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation," Tetrahedron Lett. 28(31):3539-3542
		C6.	Jager et al. (1988) Oligonucleotide N-Alkylphosphoroamidates: Synthesis and Binding to Polynucleotides,* Biochemistry 27:7237
		C7.	Agrawal et al. (1988) *Oligodeoxynucleoside Phosphoroamidates and Phosporothioates As Inhibitors of Human Immunodeficiency Virus, <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083
		C8.	Zon et al. (1991) "Phosphorothicate Oligoriculeotides" Oligonucleotides and Analogues: A Practical Approach pp. 87-108
		C9 .	Kuramoto et al. (1992) "Oligonucleotide Sequences Required For Natural Killer Ceti Activation," Jpn. J. Cancer Res. 83:1128-1131
		C10.	Crooke (1993) "An Overview of Progress in Antisense Therapeutics," 8 Antisense & Nucl. Acid Drug Dev. 115-122 CRC Press, Boca Raton, Florida
\Box		C11.	Zon (1993) "Protocols for Oliognucleotides and Analogs," Methods in Molecular Biology Vol. 20, pp. 165-189
		C12.	Pisetsky et al. (1994) Stimulation of Murine Lymphocyte Proliferation By A Phosphorothicate Ofigonucleotide With Antisense Activity For Herpes Simplex Virus, 54 Life Sci. 101
		C13.	Yamamoto et al. (1994) "Lipofection of Synthetic Oligodeoxyribonucleotide Having a Palindromic Sequence of AACGTT to Murine Spenocytes Enhances Interferon Production and Natural Killer Activity," 38 <i>Microbiol. Immunol</i> , 831
		C14.	Agrawal et al. (1995) "Modified Oligonucleotides as Therapeutic and Diagnostic Agents," Curr.Opin.Biotechnol. 6:12-19
		C15.	Krieg et al. (1995) "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," Nature 371:548-549
		C16.	Kinman et al. (1996) "CpC Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleuidn 6, Interleuidn 12, and Interleuron γ." 93 <i>Proc. Natl. Acad. Sci. USA</i> 2879
		C17.	Uang et al. (1996) "Activation of Human B Cells By Phosphorothioate Oligodeoxynucleotides," J. Clin. Invest. 98:1119-1129
		C18.	Zhao et al. (1996) "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," Biochem. Pharm. 51:173-182
1	,	C19.	Chu et al. (1997) "CpG Oligodeoxynucleotides Act As Adjuvants That Switch On T Helper 1 (Th1) Immunity," 186 J. Exp. Med. 1623

EXAMINER	DATE CONSIDERED
/Michelle Horning/	06/18/2007
EVALUED.	

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

TPE	Subt. Form PTO-1449
6.	INFORMA
FEB 0 9 T	IN AI
B.	(Use seve
CAT & THAD	Sheet

INFORMATION DISCLOSURE IN AN APPLICATION

HYB-005US4

Application Number

Docket Number

10/694,383

Applicant

(Use several sheets if necessary)

Kandimalla et al. Filing Date

Sheet 2 OF 2

Group Art Unit 10/27/03 NA

_/\	<u>/H/</u>	C20.	Duritord et al. (1997) Artisense 97: Targeting the Molecular Basis of Disease" (Nature Biotechnology) Conference Abstract, pp. 40
		C21.	Sparwasser et al. (1997) "Macrophages Sense Pathogens Via DNA Motifs: Induction of Tumor Necrosis Factor-α-Mediated Shock," 27 Eur. J. Immunol. 1671
L		C22.	Zhao et al. (1997) "Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothicate Oligonucleotides in Mice," 7 Antisense Nucleic Acid Drug. Dev. 495
		C23.	McCluside et al. (1998) *Cutting Edge: CpG DNA is A Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice,* J. Immunol. 161:4463-4466
		C24.	Moldoveanu et al. (1998) *CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus,* Vaccine 16:1216-1224
		C25.	Sparwasser et al. (1998) "Bacterial DNA and Immunostimulatory CpG Oligonucleotides Trigger Maturation and ACtivation of Murine Dendritic Cells," 28 Eur. J. Immunol. 2045
		C26.	Tokunaga et al. (1999) "How BCG Led to the Discovery of Immunostimulatory DNA " 52 Jan. J. Infact. Dis. 1
		C27.	Zhao et al. (1999) "Site of Chemical Modifications in CpG Containning Phosphorothicate Oilgodeoxynucleotide Modulates its Immunostimulatory Activity." Bioorg. & Med. Chem. Lett. 9:3453-3458
		C28.	Agrawal et al. (2000) "Antisense Therapeutics: is it As Simple As Complementary Base Recognition," 6 Mol. Med. Today 72
	\sqcup	C29.	Zhao et al. (2000) "Immunostimulatory Activity of CpG Containing Phosphorothicate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside," <i>Bloorg. & Med. Chem. Lett.</i> 10:1051-1054
<u> </u>		_c30	Agrawal et al., "Antisense therapeutics", Curr. Opin.Chem.
<u> </u>	$oldsymbol{\sqcup}$		Biol., 2:519-528, 1998.
Ь—	\blacksquare	_C31	Chaix et al., "3'-3' Linked Oligonucleotides: Synthesis and
<u> </u>	Ш		Stability Studies", Biorg. & Med.Chem., 6:827-832, 1996.
<u> </u>	_	_C32	Klinman, "therapeutic Applications of CpG-Containing Oli-
	ш		Godeoxynucleotides". Antisense & Nucl. Acid Drug Dev
	1		8:181-184, 1998.
 	-	_C33	Yu et al., "Accessible 5'-End of CpG-Containing",
├		C34	Bioorganic & Medicinal Chemistry Lett., 10:2585-2588, 2000
├─	-	CS4	
	1-	C35	Bioorganic & Medicinal Chemistry, 9:807-813, 2001.
┝ᠸ	17	تعنك	International Search Report (PCT APP. No. PCT/USO1/30137).
	//		
_	•		
 			
—			
L.			
<u> </u>			
<u> </u>			
<u> </u>			
<u> </u>			

EXAMINER DATE CONSIDERED /Michelle Horning/ 06/18/2007

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.